Keyphrases
Venous Thromboembolism
100%
Anticoagulant Therapy
42%
RIETE Registry
41%
Emblica
33%
Hereditary Hemorrhagic Telangiectasia
33%
HAART Era
33%
COVID-19
33%
Adverse Events
33%
Healthcare
33%
Adverse Health
33%
Infected Patients
33%
Patient Characterization
33%
Tertiary Hospital
33%
Developed Countries
33%
Patients with Cancer
33%
Autoimmune Disease
33%
Natural History
33%
HIV Patients
33%
Pneumocystis Jirovecii
33%
Enfermedad
33%
Superficial Vein Thrombosis
33%
Recurrent Venous Thromboembolism
27%
Deep Vein Thrombosis
25%
Highly Active Antiretroviral Therapy (HAART)
22%
Major Bleeding
20%
Anticoagulation
18%
Non-majors
16%
Cancer Patients
16%
Pulmonary Embolism
16%
Epistaxis
11%
Bleeding Events
11%
HAART Initiation
11%
Human Immunodeficiency Virus Type 1 (HIV-1)
11%
Hospital Stay
11%
Confidence Interval
11%
12-month Mortality
11%
Hazard Ratio
11%
In Care
11%
Late Presentation
11%
Bleeding
11%
Splanchnic Vein Thrombosis
8%
Differentiated Approach
8%
In Cancer
8%
Oncologists
8%
International Society
8%
Incidental
8%
Anticoagulants
8%
Cancer Treatment
8%
Thrombosis
8%
Hemostasis
8%
Medicine and Dentistry
Venous Thromboembolism
100%
Deep Vein Thrombosis
56%
Anticoagulant Therapy
40%
Highly Active Antiretroviral Therapy
33%
Hereditary Hemorrhagic Telangiectasia
33%
Human Immunodeficiency Virus
33%
Pneumocystis Jirovecii
33%
Autoimmune Disease
33%
Lower Limb
33%
Superficial Thrombophlebitis
33%
Recurrent Disease
28%
Major Bleeding
23%
Malignant Neoplasm
20%
Pulmonary Embolism
18%
Pneumocystis Pneumonia
18%
Anticoagulation
14%
Hazard Ratio
11%
Cancer Therapy
8%
Blood Stasis
8%
Phlebothrombosis
8%
Thrombosis
8%
Antithrombotic
8%
Oncologist
8%
Epistaxis
7%
Low Molecular Weight Heparin
5%
Pharmacology, Toxicology and Pharmaceutical Science
Venous Thromboembolism
66%
Deep Vein Thrombosis
48%
Vein Superficial Thrombosis
33%
Rendu Osler Weber Disease
33%
Autoimmune Disease
33%
Phyllanthus
33%
Adverse Event
33%
Malignant Neoplasm
33%
SARS Coronavirus
33%
Recurrent Disease
28%
Lung Embolism
22%
Bleeding
20%
Anticoagulant Agent
10%
Epistaxis
7%
Observational Study
6%
Disease
6%
Infection
6%
Adverse Drug Reaction
6%
Comorbidity
6%
Case Fatality Rate
6%
Low Molecular Weight Heparin
5%
